Matrix Asset Advisors’s Marker Therapeutics MRKR Stock Holding History

Matrix Asset Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$19.5K	–	109
2026 Q1	$19.5K	Hold	15,000	–	–	﹤0.01%	105
2025 Q4	$22.4K	Hold	15,000	–	–	﹤0.01%	106
2025 Q3	$13.4K	Hold	15,000	–	–	﹤0.01%	107
2025 Q2	$22.9K	Hold	15,000	–	–	﹤0.01%	108
2025 Q1	$18.4K	Hold	15,000	–	–	﹤0.01%	105
2024 Q4	$46.6K	Hold	15,000	–	–	0.01%	110
2024 Q3	$42.3K	Hold	15,000	–	–	﹤0.01%	102
2024 Q2	$81K	Hold	15,000	–	–	0.01%	101
2024 Q1	$64.5K	Hold	15,000	–	–	0.01%	100
2023 Q4	$82.5K	Hold	15,000	–	–	0.01%	98
2023 Q3	$68.1K	Sell	15,000 -25,000	-63%	-$140K	0.01%	92
2023 Q2	$124K	Buy	40,000 +15,000	+60%	+$26.1K	0.02%	95
2023 Q1	$17.8K	Hold	25,000	–	–	﹤0.01%	91
2022 Q4	$67.5K	Sell	25,000 -15,000	-38%	-$51.8K	0.01%	86
2022 Q3	$148K	Buy	40,000 +15,000	+60%	+$55.1K	0.02%	78
2022 Q2	$83K	Buy	25,000 +10,000	+67%	+$33.3K	0.01%	84
2022 Q1	$66K	Hold	15,000	–	–	0.01%	87
2021 Q4	$143K	Buy	+15,000	New	+$199K	0.02%	83

Other funds holding MRKR

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

ATPW

Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

HNB

Hilltop National Bank Casper, Wyoming $468M AUM 36.09% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Matrix Asset Advisors's MRKR Position: Q2 2026 in Review

Matrix Asset Advisors sold out of Marker Therapeutics (MRKR) in Q2 2026, closing a stake of 15,000 shares — an estimated $19.5K sold.

Matrix Asset Advisors first reported a position in MRKR in Q4 2021 and held it in 18 quarters. The position peaked at $148K in Q3 2022. 8 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

Matrix Asset Advisors reported no remaining Marker Therapeutics position as of Q2 2026 after selling out during the quarter.
Matrix Asset Advisors sold 15,000 Marker Therapeutics shares in Q2 2026, an estimated $19.5K.
Matrix Asset Advisors first reported a position in Marker Therapeutics in Q4 2021 and held it in 18 quarters.
Matrix Asset Advisors's Marker Therapeutics position peaked at $148K in Q3 2022.
8 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Matrix Asset Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.